Literature DB >> 1482155

Selection of resistant mutants of Mycobacterium avium in beige mice by clarithromycin monotherapy.

B Ji1, N Lounis, C Truffot-Pernot, J Grosset.   

Abstract

Beige mice were inoculated intravenously with 10(7.90) CFU of Mycobacterium avium 101. Among the untreated control mice, when the mean CFU per spleen increased to a level greater than 10(8), small numbers of organisms resistant to clarithromycin (CLARI) were isolated from some of the spleens; the frequency of CLARI-resistant mutants was estimated to be between 10(-8) and 10(-9). In mice treated with 200 mg of CLARI per kg of body weight six times weekly, however, CLARI-resistant organisms were isolated from the spleens of all mice examined after treatment for 8 weeks; the mean CFU per spleen and the frequency of resistant mutants were significantly greater than those of control mice and increased further after treatment for 16 weeks. The MICs of CLARI against the resistant organisms isolated from both control and treated mice were > or = 512 micrograms/ml.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1482155      PMCID: PMC245555          DOI: 10.1128/AAC.36.12.2839

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  3 in total

1.  Continuous high-grade mycobacterium avium-intracellulare bacteremia in patients with the acquired immune deficiency syndrome.

Authors:  B Wong; F F Edwards; T E Kiehn; E Whimbey; H Donnelly; E M Bernard; J W Gold; D Armstrong
Journal:  Am J Med       Date:  1985-01       Impact factor: 4.965

2.  Effect of pH on the in vitro potency of clarithromycin against Mycobacterium avium complex.

Authors:  C Truffot-Pernot; B Ji; J Grosset
Journal:  Antimicrob Agents Chemother       Date:  1991-08       Impact factor: 5.191

3.  Activity of clarithromycin against Mycobacterium avium infection in patients with the acquired immune deficiency syndrome. A controlled clinical trial.

Authors:  B Dautzenberg; C Truffot; S Legris; M C Meyohas; H C Berlie; A Mercat; S Chevret; J Grosset
Journal:  Am Rev Respir Dis       Date:  1991-09
  3 in total
  16 in total

1.  Interaction of Mycobacterium avium with human monocyte-derived dendritic cells.

Authors:  N Mohagheghpour; A van Vollenhoven; J Goodman; L E Bermudez
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

Review 2.  Prevention of the selection of clarithromycin-resistant Mycobacterium avium-intracellulare complex.

Authors:  J Grosset; B Ji
Journal:  Drugs       Date:  1997       Impact factor: 9.546

3.  Effectiveness of various antimicrobial agents against Mycobacterium avium complex in the beige mouse model.

Authors:  B Ji; N Lounis; C Truffot-Pernot; J Grosset
Journal:  Antimicrob Agents Chemother       Date:  1994-11       Impact factor: 5.191

4.  Identification of mutations in 23S rRNA gene of clarithromycin-resistant Mycobacterium intracellulare.

Authors:  A Meier; P Kirschner; B Springer; V A Steingrube; B A Brown; R J Wallace; E C Böttger
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

5.  Roxithromycin alone and in combination with either ethambutol or levofloxacin for disseminated Mycobacterium avium infections in beige mice.

Authors:  L E Bermudez; P Kolonoski; L S Young
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

6.  Efficacies of liposome-encapsulated clarithromycin and ofloxacin against Mycobacterium avium-M. intracellulare complex in human macrophages.

Authors:  C O Onyeji; C H Nightingale; D P Nicolau; R Quintiliani
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191

Review 7.  Mycobacterium avium complex: advances in therapy.

Authors:  D V Havlir
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-11       Impact factor: 3.267

Review 8.  Clarithromycin. A review of its pharmacological properties and therapeutic use in Mycobacterium avium-intracellulare complex infection in patients with acquired immune deficiency syndrome.

Authors:  L B Barradell; G L Plosker; D McTavish
Journal:  Drugs       Date:  1993-08       Impact factor: 9.546

9.  Anticytomegaloviral activity of methotrexate associated with preferential accumulation of drug by cytomegalovirus-infected cells.

Authors:  M Wachsman; F M Hamzeh; H Saito; P S Lietman
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

10.  How effective is KRM-1648 in treatment of disseminated Mycobacterium avium complex infections in beige mice?

Authors:  B Ji; N Lounis; C Truffot-Pernot; J Grosset
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.